ATS 2019 Virtual Final Program

P1136 Inhibition of Matrikine Signaling Ameliorates Hypoxic Mediated Pulmonary Hypertension/ D. Xing, J.W. Barnes, S. Krick, C. McNicholas, E.S. Helton, Y. Wu, L. Viera, J.E. Blalock, J.M. Wells, Birmingham, AL, p.A5062 P1137 Mitomycin C Induces Pulmonary Vessel Endothelial-To-Mesenchymal Transition and Pulmonary Veno-Occlusive Disease via Smad3-Dependent Pathway in Rats/ C. Zhang, S. Liu, X. Luo, Guangzhou, China, p.A7401 CLINICAL THEMATIC POSTER SESSION C51 CLOSER TO THE HEART: UPDATE ON APPROVED THERAPIES FOR PAH 9:15 a.m. - 4:15 p.m. KBHCCD Area J (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitators : E.D. Austin, MD, MSc, Nashville, TN D. Fraidenburg, MD, Chicago, IL P1139 Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension: Final Data Cut from the EXPERT Registry/ M. Hoeper, H. Gall, E. Grünig, H. Klose, M. Halank, D. Langleben, R.J. Snijder, P. Escribano, L.M. Mielniczuk, T. Lange, J.-L.E. Vachiéry, H. Wirtz, D.S. Helmersen, I. Tsangaris, J.A. Barberá, J. Pepke-Zaba, A. Boonstra, S. Rosenkranz, S. Ulrich, R. Steringer_Mascherbauer, M.A. Gomez Sanchez, M. Humbert, D. Pittow, G. Simonneau, J. Klotsche, E. Williams, C. Meier, H.A. Ghofrani, Hannover, Germany, p.A5063 P1140 Assessment of the REPLACE Study Composite Endpoint in the PATENT Study and Association with Long-Term Outcomes in Riociguat-Treated Patients/ G. Simonneau, M.M. Hoeper, H.A. Ghofrani, P. Corris, S. Rosenkranz, E. Grünig, R.J. White, V.V. McLaughlin, D. Langleben, R.L. Benza, Le Kremlin-Bicêtre, France, p.A5064 P1141 An Evaluation of the Effect of Macitentan on the Pharmacokinetics of Riociguat in Healthy Male Subjects/ D. Csonka, S. Bruderer, A. Schultz, R. Stepanova, J.J. Perez Ruixo, Allschwil, Switzerland, p.A5065 P1142 Real-World Dosing Characteristics of Parenteral Treprostinil/ V. Balasubramanian, L. Melendres-Groves, Z. Safdar, M. Broderick, M. Sketch, L. Chen, A. Nelsen, Fresno, CA, p.A5066 P1143 A Single Center Experience of Transitioning Stable Pulmonary Arterial Hypertension Patients from Parenteral Prostacyclin Therapy to Oral Selexipag/ T.G. Shah, O. Igenoza, S. Bartolome, F. Torres, M. Kingman, S. Harden, K.M. Chin, Dallas, TX, p.A5067 P1144 Use of Aerosolized Prostacyclins in Critically Ill Patients and Association with Clinical Outcomes/ S. Hussain, H.A. Jaliawala, J. Tsui, B.R. Brown, R.J. Bernardo, Oklahoma City, OK, p.A5068 P1145 Fulvestrant May Increase Six Minute Walk Distance in Pulmonary Arterial Hypertension (PAH)/ D. Pinder, A. McCormick, M. Patel, J.S. Fritz, K.A. Smith, J.A. Mazurek, D.B. Taichman, N. Al-Naamani, C. Burwell, C.L. Archer-Chicko, H.I. Palevsky, A. DeMichele, D. Mankoff, S.M. Kawut, Philadelphia, PA, p.A5069 P1146 A Phase 1, Open-Label, Randomized, Single Dose, Replicate Four-Way, Crossover Study to Assess the Bioequivalence of Esuberaprost Potassium Tablets and Esuberaprost Sodium Tablets in Healthy Subjects/ K.R.B. von Kessler, H. Coleman, S. Hossack, M. Dunn, R. Habaradas, J. Shin, P. Sista, Silver Spring, MD, p.A5070 P1147 Continuous Parenteral Prostanoids in Severe Group III Pulmonary Hypertension/ C.A. Hinkamp, T.G. Shah, S. Bartolome, F. Torres, K.M. Chin, Dallas, TX, p.A5071 Facilitators : R.J. White, MD, PhD, Rochester, NY D.B. Badesch, MD, Aurora, CO P1148 Effect of Transitioning from Phosphodiesterase Type 5 Inhibitors to Riociguat/ K. Sun, T. Kendzerska, L. Mielniczuk, D.J. Stewart, V. Contreras-Dominguez, C. Pugliese, R. Dunne, R. Davies, J. Foxall, G. Chandy, Ottawa, Canada, p.A5072 P1149 Treprostinil as a Bridge Therapy to Heart-Lung Transplants in Severe Pulmonary Arterial Hypertension/ C. Ju, Q. Lian, B. Wei, X. Xu, J. He, R. Chen, Guangzhou, China, p.A5073 P1150 Study Design of the Phase 3 ADVANCE Program Evaluating Time-to-Clinical Events and Exercise Capacity in Patients with Pulmonary Arterial Hypertension Treated with Ralinepag/ V.V. McLaughlin, R. Channick, B. Walsh, M. Keating, K. Gilder, C. Cabell, P. Klassen, V.F. Tapson, M. Humbert, Ann Arbor, MI, p.A5074 P1151 The Long Term Experience on Treatment for Adult Patients with Eisenmenger Syndrome/ Z. Dai, I. Chen, J. Hsu, Y. Wu, Y. Liu, Kaohsiung P1152 Improving Appropriate Use of Oral Prostacyclin Therapy: Effectiveness of Online CME/ J. Spyropoulos, K. Hanley, New York, NY, p.A5076 P1153 Clinical Course of Patients Enrolled in SPHERE (SelexiPag: The Users Drug Registry), a US Pulmonary Arterial Hypertension (PAH) Registry: One-Year Follow-Up/ K.B. Highland, K.M. Chin, V. McLaughlin, N.H. Kim, H.W. Farber, M.M. Chakinala, C. Zhao, J. Colvin, M. Shah, A.R. Hemnes, Cleveland, OH, p.A5077 P1154 Changes in Risk Category Among Patients with Systemic Sclerosis-Associated PAH Treated with Initial Combination Therapy in the ATPAHSS Trial/ V. Mercurio, S.C. Mathai, R.L. Damico, T.M. Kolb, C. Simpson, P.M. Hassoun, Baltimore, MD, p.A5078 P1155 INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in PULMONARY ARTERIAL HYPERTENSION (PAH) (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil NCT03399604)/ N.S. Hill, J.P. Feldman, S. Sahay, D.J. Levine, R.F. Roscigno, T.A. Vaughn, T.M. Bull, Boston, MA, p.A7402 ATS 2019 • Dallas, TX 264 TUESDAY • MAY 21